NEW YORK (GenomeWeb News) – Galapagos said today that it has acquired the drug discovery services assets of Cambridge, UK-based Sareum Holdings for €695,000 ($1 million).
Sareum’s drug discovery services business uses x-ray crystallography to identify chemical fragments for recombination into lead compounds. The services and technology assets will be integrated into Galapagos’ BioFocus DPI unit.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.